Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1990 Sep;28(9):1988–1993. doi: 10.1128/jcm.28.9.1988-1993.1990

Comparison of immunofluorescence, particle agglutination, and enzyme immunoassays for detection of human T-cell leukemia virus type I antibody in African sera.

M Verdier 1, F Denis 1, G Leonard 1, A Sangare 1, S Patillaud 1, M Prince-David 1, M Essex 1
PMCID: PMC268091  PMID: 2229382

Abstract

The effectiveness of four screening tests for detecting antibody to human T-cell leukemia virus type I (HTLV-I) was determined by using 2,700 African serum specimens. The tests studied were indirect immunofluorescence, particle agglutination from Fujirebio, and two enzyme immunoassays, one from Abbott Laboratories that used virus lysate from HUT 102 cells and the other from Cambridge BioScience Corp. that used an env recombinant protein. Positive and doubtful sera were confirmed by Western immunoblot and radioimmunoprecipitation assay with Food and Drug Administration seropositivity criteria. The best results were obtained with the two enzyme immunoassays, which were more sensitive (100 and 98.6% [Abbott and Cambridge, respectively]) and more specific (98.7 and 96.5%). Indirect immunofluorescence exhibited difficulties for reading and interpretation. With particle agglutination, prozone was observed for 9 of 78 HTLV-I-positive serum specimens. False-positives in any of the tests were not linked to cross-reactions with human immunodeficiency viruses. However, confirmation tests remain necessary for HTLV-I screening.

Full text

PDF
1988

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agius G., Biggar R. J., Alexander S. S., Waters D. J., Drummond J. E., Murphy E. L., Weiss S. H., Levine P. H., Blattner W. A. Human T lymphotropic virus type I antibody patterns: evidence of difference by age and risk group. J Infect Dis. 1988 Dec;158(6):1235–1244. doi: 10.1093/infdis/158.6.1235. [DOI] [PubMed] [Google Scholar]
  2. Chen Y. M., Lee T. H., Samuel K. P., Okayama A., Tachibana N., Miyoshi I., Papas T. S., Essex M. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people. J Virol. 1989 Nov;63(11):4952–4957. doi: 10.1128/jvi.63.11.4952-4957.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gallo D., Hoffman M. N., Cossen C. K., Diggs J. L., Hurst J. W., Penning L. M. Comparison of immunofluorescence, enzyme immunoassay, and Western blot (immunoblot) methods for detection of antibody to human T-cell leukemia virus type I. J Clin Microbiol. 1988 Aug;26(8):1487–1491. doi: 10.1128/jcm.26.8.1487-1491.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ikeda M., Fujino R., Matsui T., Yoshida T., Komoda H., Imai J. A new agglutination test for serum antibodies to adult T-cell leukemia virus. Gan. 1984 Oct;75(10):845–848. [PubMed] [Google Scholar]
  5. Ishizaki J., Okayama A., Tachibana N., Yokota T., Shishime E., Tsuda K., Mueller N. Comparative diagnostic assay results for detecting antibody to HTLV-I in Japanese blood donor samples: higher positivity rates by particle agglutination assay [corrected]. J Acquir Immune Defic Syndr. 1988;1(4):340–345. [PubMed] [Google Scholar]
  6. Kobayashi S., Yoshida T., Hiroshige Y., Matsui T., Yamamoto N. Comparative studies of commercially available particle agglutination assay and enzyme-linked immunosorbent assay for screening of human T-cell leukemia virus type I antibodies in blood donors. J Clin Microbiol. 1988 Feb;26(2):308–312. doi: 10.1128/jcm.26.2.308-312.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kwon K. W., Ikeda H., Yano M., Sekiguchi S. Evaluation of the human T-cell leukemia virus type I seropositivity of blood donors by the particle agglutination inhibition test. Jpn J Cancer Res. 1989 Sep;80(9):833–839. doi: 10.1111/j.1349-7006.1989.tb01723.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lee H., Swanson P., Shorty V. S., Zack J. A., Rosenblatt J. D., Chen I. S. High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science. 1989 Apr 28;244(4903):471–475. doi: 10.1126/science.2655084. [DOI] [PubMed] [Google Scholar]
  9. Maeda Y., Imai J., Kiyokawa H., Kanamura M., Hino S. Performance certification of gelatin particle agglutination assay for anti-HTLV-1 antibody: inconclusive positive results. Jpn J Cancer Res. 1989 Oct;80(10):915–919. doi: 10.1111/j.1349-7006.1989.tb01625.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Román G. C. Retrovirus-associated myelopathies. Arch Neurol. 1987 Jun;44(6):659–663. doi: 10.1001/archneur.1987.00520180073022. [DOI] [PubMed] [Google Scholar]
  11. Verdier M., Denis F., Sangaré A., Barin F., Gershy-Damet G., Rey J. L., Soro B., Léonard G., Mounier M., Hugon J. Prevalence of antibody to human T cell leukemia virus type 1 (HTLV-1) in populations of Ivory Coast, West Africa. J Infect Dis. 1989 Sep;160(3):363–370. doi: 10.1093/infdis/160.3.363. [DOI] [PubMed] [Google Scholar]
  12. Yoshida M., Miyoshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031–2035. doi: 10.1073/pnas.79.6.2031. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES